Abstract
Guanine-Based Purines as an Innovative Target to Treat Major Depressive Disorder.
Highlights
Major depressive disorder (MDD) is the most prevalent psychiatric disorder worldwide, and the leading disability causes a well-documented syndrome (Liu et al, 2020)
As a result until 2009, except for the nonmainstream agomelatine (Norman and Olver, 2019), all antidepressants in the clinic acted by modulating monoaminergic neurotransmission (Berton and Nestler, 2006)
Since ketamine modulates purinergic neurotransmission, the ketamine-induced nucleotide and NADPH augmentation might be, at least in part, responsible for the cell proliferation, morphogenesis, and protein synthesis observed after ketamine administration, all of which are relevant for its antidepressant effect
Summary
Major depressive disorder (MDD) is the most prevalent psychiatric disorder worldwide, and the leading disability causes a well-documented syndrome (Liu et al, 2020). A single ketamine administration increases mice plasma levels of PPP intermediates (D-ribose-5-phosphate and D-ribulose-5-phosphate), the substrates for purine de novo synthesis (McGowan et al, 2018).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
